Carbon Bonded Directly At The 17 Beta-position Of The Cyclopentanohydrophenanthrene Ring System Is A Member Of An Acyclic Chain Of Three Or Four Uninterruped Carbons, (e.g., Diketobisnorcholenic Acids, Etc.) Patents (Class 552/553)
  • Patent number: 10000526
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 19, 2018
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Pröls, Erik Fischer, Heidi Waenerlund Poulsen
  • Patent number: 9512167
    Abstract: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: December 6, 2016
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Markus Proels, Erik Fischer, Heidi Waenerlund Poulsen
  • Patent number: 9090652
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 28, 2015
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Publication number: 20150112089
    Abstract: This disclosure relates to deuterated bile acid compositions. A deuterated compound is selected from the disclosed groups of bile acids and their derivatives, analogs and salts. At least one of the hydrogen atoms in the compound is replaced with deuterium.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 23, 2015
    Applicant: Metselex, Inc.
    Inventors: Michael D. Finch, Walter Low, Clifford Steer, Cyrus B. Munshi, Cecilia Rodrigues, Susana Dias Lucas de Oliveira
  • Publication number: 20150094261
    Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Inventors: Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
  • Publication number: 20150094291
    Abstract: The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 2, 2015
    Applicant: Opendot Research Co Limited
    Inventor: Derek John GOLDSMITH
  • Patent number: 8975310
    Abstract: A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. The hydrophobic CSA also includes a hydrophobic substituent that gives the ceragenin compound a CLogP value of at least 6.5.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: March 10, 2015
    Assignee: Brigham Young University
    Inventor: Paul B. Savage
  • Patent number: 8933077
    Abstract: Provided are compounds of Formula I wherein R1, R2, Y, Z and G are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: January 13, 2015
    Assignee: Array BioPharma Inc.
    Inventors: Thomas D. Aicher, Ronald Jay Hinklin, Mark Joseph Chicarelli, Steven Armen Boyd, Kevin Ronald Condroski, Yi-Wen Yeh
  • Publication number: 20140371190
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.
    Type: Application
    Filed: May 14, 2014
    Publication date: December 18, 2014
    Inventor: Roberto Pellicciari
  • Publication number: 20140343023
    Abstract: The present invention relates to compounds of formula I, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention, suppression or amelioration of a disease mediated by the ROR gamma receptor in a subject in need thereof, in particular diabetes and diabetes-related disorders, specifically type II diabetes, methods of their production, as well as methods of treatment or prevention of such diseases.
    Type: Application
    Filed: September 18, 2012
    Publication date: November 20, 2014
    Inventors: Christian Wolfrum, Erick Carriera, Bettina Meissburger
  • Patent number: 8853431
    Abstract: The present invention relates to a process for the preparation of 17?-(3-hydroxypropyl)-17?-hydroxysteroids of the formula I starting from 17-ketosteroids of the formula III via the intermediates of the formula V wherein the radicals R3, R5, R6, R7, R10, R13, R15, R16, R40, R41 and R42 have the meaning indicated in the description.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: October 7, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Claus Christian Haeselhoff, Mike Petersen
  • Patent number: 8796249
    Abstract: The invention relates to compounds of Formula A: (A) or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: August 5, 2014
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Publication number: 20140206657
    Abstract: Provided herein are bile acid analogues and derivatives, methods of synthesizing bile acid analogues and derivatives and their use in treating diabetes and liver disease.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Applicant: City of Hope
    Inventors: Donna Yu, Barry Forman, Wendong Huang, Kyle Sousa
  • Patent number: 8741882
    Abstract: The preset invention relates to a new oral anti-diabetic compound prepared by synthesizing a steroid and a guanide or biguanide, which is eliminated via the hepatic route, instead of the renal route, to avoid adverse effects of administering metformin in diabetic patients with renal dysfunction. A pharmaceutical composition comprising the compound of the invention and the method for treating diabetes using the compound are also provided.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 3, 2014
    Assignee: Sen Capital, LLC.
    Inventor: John Soong
  • Publication number: 20140100209
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 10, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: Intercept Pharmaceuticals, Inc.
  • Publication number: 20140057886
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: August 28, 2013
    Publication date: February 27, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Publication number: 20140024631
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Application
    Filed: February 7, 2013
    Publication date: January 23, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventor: INTERCEPT PHARMACEUTICALS, INC.
  • Publication number: 20140024630
    Abstract: The present invention refers to a method for the non-surgical treatment of a lypodistrophy caused by an antiretroviral therapy in an individual infected by a retrovirus, such as HIV, and undergoing said antiretroviral therapy said method comprising the step of administering an effective amount of a adipocitolytic composition comprising deoxycholic acid and/or a pharmaceutically acceptable salt thereof in a retrovirus-infected individual affected by said lipodistrophy.
    Type: Application
    Filed: July 19, 2012
    Publication date: January 23, 2014
    Inventor: Raffaele RAUSO
  • Patent number: 8586770
    Abstract: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a condition where cell or tissue repair is needed.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: November 19, 2013
    Assignee: Harbor Therapeutics, Inc.
    Inventor: James M. Frincke
  • Patent number: 8546365
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: October 1, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Publication number: 20130190517
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.
    Type: Application
    Filed: December 28, 2012
    Publication date: July 25, 2013
    Inventor: KYTHERA BIOPHARMACEUTICALS, INC.
  • Publication number: 20130190280
    Abstract: The preset invention relates to a new oral anti-diabetic compound prepared by synthesizing a steroid and a guanide or biguanide, which is eliminated via the hepatic route, instead of the renal route, to avoid adverse effects of Metformin, such as renal dysfunction. A pharmaceutical composition comprising the compound of the invention and the method for treating diabetes using the compound are also provided.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 25, 2013
    Inventor: John Soong
  • Publication number: 20130143850
    Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.
    Type: Application
    Filed: June 16, 2011
    Publication date: June 6, 2013
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Nicolette Farman, Francine Behar-Cohen, Frédéric Jaisser
  • Publication number: 20130137884
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-?-hydroxy-steroids from ?-9,11-ene, 11-keto or 11-hydroxy-?-steroids. This invention is also directed to novel compounds prepared during the synthesis. This invention is also directed to the synthesis of deoxycholic acid starting from hydrocortisone.
    Type: Application
    Filed: December 17, 2010
    Publication date: May 30, 2013
    Inventors: Robert M. Moriarty, Achampeta Rathan Prasad, John Gregory Reid, Roy A. Swaringen, JR.
  • Publication number: 20130102580
    Abstract: Provided herein are polymorphic forms of deoxycholic acid (DCA), improved methods of synthesizing DCA and intermediates thereto, and compositions and fat removal methods employing the DCA as provided herein.
    Type: Application
    Filed: September 20, 2012
    Publication date: April 25, 2013
    Applicant: Kythera Biopharmaceuticals, Inc.
    Inventor: Kythera Biopharmaceuticals, Inc.
  • Publication number: 20130053507
    Abstract: A hydrophobic cationic steroidal anti-microbial (ceragenin) compound forms an amphiphilic compound having a hydrophobic sterol face and a hydrophilic cationic face. The hydrophobic CSA also includes a hydrophobic substituent that gives the ceragenin compound a CLogP value of at least 6.5.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 28, 2013
    Inventor: Paul B. Savage
  • Publication number: 20130029953
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 31, 2013
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Patent number: 8338628
    Abstract: A novel, improved method of synthesizing alkylated bile acid derivatives is provided. Such derivatives include, but are not limited to the active, potent, and selective FXR receptor agonist such as 6-ECDCA and other CA, DCA and CDCA derivatives. The first step of the synthesis selectively oxidates CDCA, CD, or DCA related starting material. An efficient combined deprotonation, trapping, ethylation, deprotection and reduction system is used to produce the desired alkylated bile acid derivatives. This practical synthesis offers a simple and economical pathway suitable for a large-scale manufacturing of alkylated bile acid derivatives including, but not limited to, 6-ECDCA.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: December 25, 2012
    Assignee: City of Hope
    Inventors: Donna D. Yu, Barry M. Forman
  • Publication number: 20120309728
    Abstract: The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.
    Type: Application
    Filed: December 17, 2010
    Publication date: December 6, 2012
    Inventors: Catherine Grenot, Claude Cuilleron
  • Publication number: 20120283234
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: April 7, 2011
    Publication date: November 8, 2012
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Publication number: 20120283217
    Abstract: As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.
    Type: Application
    Filed: July 16, 2012
    Publication date: November 8, 2012
    Applicant: SATORI PHARMACEUTICALS, INC.
    Inventors: Mark A. Findeis, Steffen P. Creaser
  • Publication number: 20120277448
    Abstract: A method for preparing 3?-arachidylamido-7?,12?,5?-cholan-24-carboxylic acid represented by the following formula V is disclosed, which includes the following steps: converting cholic acid to the compound of formula III by acylation reaction and azidation reaction, reducing the compound of formula III to the compound of formula IV and in the end acylating the compound of formula IV with arachidoyl chloride to get the compound of formula V. The method avoids the use of protection groups.
    Type: Application
    Filed: November 25, 2010
    Publication date: November 1, 2012
    Applicants: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Xiangrui Jiang, Lijun Guo, Yiru Dai, Jianfeng Li, Jin Suo, Rongxia Zhang, Zheng Liu
  • Patent number: 8258146
    Abstract: An object of the present invention is to provide a liquid composition wherein minoxidil can be dissolved at a relatively high concentration (the saturating amount or above), stimulation of skin and stickiness is suppressed without containing an organic solvent, and excellent effects of percutaneous absorption is achieved. The present invention provides a liquid composition comprising (i) minoxidil, (ii) bile acid or a salt thereof, and (iii) an aqueous medium in an amount of 30% by weight or more of the weight of the composition.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: September 4, 2012
    Assignee: FUJIFILM Corporation
    Inventors: Ritsuko Morita, Katsuhiko Kanazawa
  • Publication number: 20120196227
    Abstract: A chemically amplified positive resist composition comprises an acid-decomposable keto ester compound of steroid skeleton which is insoluble in alkaline developer, but turns soluble in alkaline developer under the action of acid. The composition is exposed to EB, deep-UV or EUV and developed to form a pattern with a high resolution and improved LER.
    Type: Application
    Filed: January 31, 2012
    Publication date: August 2, 2012
    Applicant: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Takeru WATANABE, Tomohiro KOBAYASHI, Katsuya TAKEMURA, Jun HATAKEYAMA
  • Publication number: 20120115832
    Abstract: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
    Type: Application
    Filed: December 7, 2011
    Publication date: May 10, 2012
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Publication number: 20120048285
    Abstract: Compositions are provided which contain immobilized flavorants, in the form of supramolecular complexes of flavorant compounds, for flavor delivery. One embodiment relates to the flavorant supramolecular complexes themselves; Other embodiments relate compositions which contain the flavorant supramolecular complexes and a substrate. In particular embodiments, the substrate is smokable, but in other embodiments may be non-smokable or comestible.
    Type: Application
    Filed: March 25, 2011
    Publication date: March 1, 2012
    Applicant: Philip Morris USA Inc.
    Inventors: Munmaya K. Mishra, Biao Duan, Peter J. Lipowicz, William R. Sweeney
  • Publication number: 20120035116
    Abstract: This invention relates to methods of preserving the integrity of peptides in the gut. In particular it concerns the use of certain compounds as inhibitors of gut proteases. Compounds identified as having gut protease inhibitory activity are biguanides, certain bile acids and pharmaceutically acceptable salts of these compounds. This activity makes these compounds useful for co-administration with prophylactic or therapeutic peptides. This invention relates to methods of inhibiting gut proteases and peptide formulations comprising these gut protease inhibitor.
    Type: Application
    Filed: October 1, 2009
    Publication date: February 9, 2012
    Inventors: Roger R., C. New, Glen Travers
  • Publication number: 20110263555
    Abstract: The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease.
    Type: Application
    Filed: November 19, 2009
    Publication date: October 27, 2011
    Inventor: Roberto Pellicciari
  • Publication number: 20110263546
    Abstract: The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertension. The invention also provides, in part, polyhydroxylated bile acids for stimulating bile flow.
    Type: Application
    Filed: February 26, 2009
    Publication date: October 27, 2011
    Inventors: Renxue Wang, Victor Ling, Jonathan Ahab Sheps
  • Publication number: 20110250537
    Abstract: New photoacid generator compounds (“PAGs”) are provided that comprise a cholate moiety and photoresist compositions that comprise such PAG compounds.
    Type: Application
    Filed: December 10, 2010
    Publication date: October 13, 2011
    Applicant: Rohm and Haas Electronic Materials LLC
    Inventors: Emad AQAD, Mingqi Li, Joseph Mattia, Cheng-Bai Xu
  • Publication number: 20110224448
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.
    Type: Application
    Filed: May 25, 2011
    Publication date: September 15, 2011
    Inventors: Achampeta Rathan Prasad, Roy A. Swaringen, JR., John Gregory Reid, Robert M. Moriarty, Akhila Kumar Sahoo
  • Publication number: 20110172198
    Abstract: The invention relates to compounds of Formula A: (A) or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.
    Type: Application
    Filed: July 30, 2009
    Publication date: July 14, 2011
    Applicant: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Publication number: 20110152552
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.
    Type: Application
    Filed: January 20, 2011
    Publication date: June 23, 2011
    Inventors: Achampeta Rathan Prasad, Roy A. Swaringen, JR., John Gregory Reid, Robert M. Moriarty, Akhila Kumar Sahoo
  • Publication number: 20110144281
    Abstract: The present invention relates to a polymer comprising a cholane core having at least one derivatizable group covalently bonded thereto and a hydrophilic polymer chain covalently bonded to derivatizable group(s) and a process for producing it The present invention also relates to micellar aggregate formed from the polymer of the present.
    Type: Application
    Filed: December 5, 2008
    Publication date: June 16, 2011
    Applicant: VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE
    Inventors: Xiao-Xia Zhu, Juntao Luo, Guillaume Giguere
  • Publication number: 20110098260
    Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.
    Type: Application
    Filed: December 1, 2010
    Publication date: April 28, 2011
    Applicant: Harbor BioSciences, Inc.
    Inventor: James M. Frincke
  • Patent number: 7932244
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: April 26, 2011
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Publication number: 20110086829
    Abstract: Compositions and methods for treating obesity in a subject are described. Some embodiments provide methods for administering pharmaceutical formulations including biocompatible emulsifiers in an amount effective to treat obesity. In some embodiments, pharmaceutical formulations include a combination of two or more biocompatible emulsifiers effective to treat obesity.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 14, 2011
    Inventors: Filiberto P. Zadini, Giorgio C. Zadini
  • Patent number: 7906137
    Abstract: A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include ?-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N?-deoxycholyl-L-lysine-methylester. The delivery agent and the biologically active agent are mixed together to form a complex, which is then administered to the animal. These complexes are particularly useful for oral administration of biologically active agents, but other routes of administration may be used.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: March 15, 2011
    Assignee: Mediplex Corporation, Korea
    Inventors: Youngro Byun, Seulki Lee, Hyuntae Moon
  • Publication number: 20110059932
    Abstract: Compounds of formula (I): in which R1, R2, R3, R3?, R4, R5, R6, R6?, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, A, D, X, Y, and Z are defined in the specification. Also disclosed is a method of using one of the compounds to lower the blood cholesterol level and treat cancer, atherosclerosis, diabetes, Alzheimer's disease, and corneal arcus.
    Type: Application
    Filed: July 29, 2010
    Publication date: March 10, 2011
    Applicant: The University of Chicago
    Inventors: Dacheng Peng, John Kokontis, Richard Hiipakka, Shutsung Liao
  • Publication number: 20110038847
    Abstract: A process for preparing a bioabsorbable sheet preparation holding thrombin is provided. A process for preparing a bioabsorbable sheet preparation holding thrombin which comprises immersing a bioabsorbable sheet consisting of polyglycolic acid in a thrombin solution containing thrombin as an active ingredient, glycerol as a softening agent, Tween 80 as a permeating agent, and optionally histidine and trehalose as a stabilizing agent followed by drying to hold thrombin on said bioabsorbable sheet, and a bioabsorbable sheet preparation holding thrombin prepared by said process.
    Type: Application
    Filed: April 15, 2009
    Publication date: February 17, 2011
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Ryoichi Kawamura, Takayuki Imamura, Hitomi Owaki